STEVENSON, Md., Sept. 28, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A
Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the
Southern District of New York on behalf of purchasers of Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (“Intercept” or the
“Company”) securities during the period between May 31, 2016 and September 20, 2017, inclusive (the “Class Period”).
Investors who wish to become proactively involved in the litigation have until November 27, 2017 to seek appointment as lead
plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and
be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including
whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants
claiming the largest loss from investment in Intercept securities during the Class Period. Members of the class will be
represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above
action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the
defendants’ failure to disclose during the Class Period that Ocaliva entailed undisclosed safety risks, including death, to
patients suffering from primary biliary cirrhosis (PBC).
According to the complaint, following a September 12, 2017 letter warning physicians against overdosing patients
with Ocaliva and advising them that the drug has been tied to liver injuries and death among patients from PBC, and a September 21,
2017 safety announcement by the Food and Drug Administration after reports of multiple deaths, the value of Intercept shares
declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Intercept securities purchased on or after
May 31, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to
learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit
our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more
information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and
have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower
Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at
this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
hoffman@browerpiven.com
